Drug Trial Radar · NCT07900451
Multimodal Biomarkers Predicting Medication-Induced Adverse Effects in Children With ADHD
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Aug 1, 2026
Primary completion
Jul 31, 2029
Study completion Jul 31, 2029
Sponsor
- Lead sponsor
- National Taiwan University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 28, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To build a multimodal model combining neuropsychological, neurophysiological, and metabolomic measures to identify biomarkers predicting MPH-induced adverse effects and their underlying mechanisms, supporting individualized risk assessment in clinical practice.
Conditions
- ADHD
Interventions
methylphenidateDrug
The patients with ADHD will receive 16-week treatment with methylphenidate.
Primary outcomes
What the sponsor says the trial is designed to measure.
- QuestionnaireTime frame: 5 minutes
- Diagnostic interviewTime frame: 1 hour
- ADHD symptomsTime frame: 15 minutes
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Taiwan University Hospital
Taipei, Taiwan, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.